ETOP 22-22 ADEPPT: A multicentre, single-arm phase II trial of adagrasib in patients with KRASG12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510463-35-00

Acronym

ETOP 22-22 ADEPPT

Enrollment

Registered

2024-03-13

Start date

2023-04-26

Completion date

Unknown

Last updated

2025-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

including patients aged ≥18 years with poor performance status (ECOG PS=2) Cohort 1 or elderly (≥70 years) (ECOG PS=0-1) Cohort 2, Patients with KRASG12C-mutant NSCLC

Brief summary

Objective Response Rate (ORR) per RECIST v1.1, assessed at 12 weeks.

Detailed description

- Durable clinical benefit (DCB) - Time to progression (TTP) - Progression-free Survival (PFS) - Overall Survival (OS) - Safety - Patient-related outcomes

Interventions

DRUGAdagrasib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective Response Rate (ORR) per RECIST v1.1, assessed at 12 weeks.	—

Secondary

Measure	Time frame
- Durable clinical benefit (DCB) - Time to progression (TTP) - Progression-free Survival (PFS) - Overall Survival (OS) - Safety - Patient-related outcomes	—

Countries

Belgium, France, Ireland, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026